Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
Tevogen Bio Partners with Databricks to Advance AI-Driven Immunotherapy Target Prediction Platform
Tevogen Bio has commissioned Databricks to accelerate development of PredicTcell, its proprietary AI-driven target prediction model for precision immunotherapy.
Tevogen Bio Files Patent for Novel T Cell Vaccine Targeting Entire Viral Genomes
Tevogen Bio has filed a USPTO patent for a unique T cell vaccine designed to target entire viral genomes, potentially overcoming mutation-based resistance seen with traditional vaccines.
Tevogen Bio Secures In-House Cell Therapy Production Facility to Accelerate T Cell Therapeutics Development
Tevogen Bio has finalized an agreement with CD8 Technology Services to develop a turn-key facility supporting both pre-clinical research and GMP cell therapy production capabilities.
Tevogen Bio Presents ExacTcell Platform to BARDA as Potential Rapid-Response Viral Countermeasure
Tevogen Bio met with BARDA TechWatch team to showcase their ExacTcell technology, highlighting its potential as a scalable medical countermeasure against emerging viral threats.
Tevogen Bio CEO Highlights Commitment to Patient Accessibility and Business Model
Tevogen Bio's CEO, Dr. Saadi, reaffirmed his dedication to making therapeutics accessible to patients through the company's innovative business model.
Tevogen Bio's TVGN 489 Shows Promise in High-Risk COVID-19 Patients
Tevogen Bio's TVGN 489, an allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes immunotherapy, demonstrates promising results in a Phase I clinical trial.